查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1865445

医疗保健IPO市场预测至2032年：按营业单位类型、IPO规模和结构、投资者类型、上市市场、治疗领域和地区分類的全球分析

Healthcare IPOs Market Forecasts to 2032 - Global Analysis By Entity Type, IPO Size & Structure, Investor Type, Listing Venue, Therapeutic Area and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计 2025 年全球医疗保健 IPO 市场规模将达到 18 亿美元，到 2032 年将达到 28 亿美元，预测期内复合年增长率为 6.3%。

医疗保健IPO是指医疗保健产业公司（包括製药、生技、医疗设备、诊断和数位医疗）的首次公开发行（IPO）。这些IPO使私人医疗保健公司能够首次向公众发行股票，以筹集资金用于扩张、研发和创新。医疗保健IPO通常受医疗技术创新、监管核准以及投资者对生命科学领域的兴趣所驱动，而生命科学领域在为高成长企业提供资金和扩大公众获得最先进治疗的机会方面发挥着关键作用。市场趋势可能受到临床试验结果、政策变化和更广泛的经济状况的影响。

医疗保健技术的快速创新

医疗保健技术的快速创新是推动医疗保健IPO市场发展的关键因素。生物技术、数位医疗、人工智慧驱动的诊断以及穿戴式医疗设备等领域的突破性进展正在改变患者照护，并创造成长机会。这些进步吸引了投资人的关注，并加速了企业上市进程。Start-Ups和成熟公司都在探索IPO，以资金筹措、扩大营运规模并将创新疗法商业化。随着医疗保健技术的不断发展，它正在推动充满活力的IPO市场，从而支持创新并扩大尖端医疗保健解决方案的覆盖范围。

更严格的IPO标准

更严格的IPO标准是阻碍因素要求，以确保透明度、财务稳定性和投资者保护。这些要求包括严格的财务资讯揭露、临床试验检验和管治标准。虽然这些措施有助于维护市场诚信，但也可能导致IPO计划延迟甚至终止，尤其对于早期医疗保健公司。克服这些障碍需要完善的合规策略和投资者关係准备，这可能会使一些公司难以有效率地进入公开资本市场。

数位医疗的扩展

数位医疗的蓬勃发展为医疗健康领域的IPO市场带来了巨大的机会。远端医疗、远端监测、人工智慧诊断和健康数据平台正在重塑医疗服务模式。在对便利、科技驱动型医疗服务日益增长的需求驱动下，数位医疗Start-Ups正在筹集大量创业投资，并积极筹备上市。 IPO能够为这些企业提供必要的资金，以扩大平台规模、加强网路安全并拓展全球业务。这场数位转型正在催生新的收入来源，并将医疗健康领域的IPO打造成为通往下一代医疗创新的入口。

监理复杂性

监管的复杂性对医疗保健IPO市场构成重大威胁。寻求上市的公司面临着应对不同司法管辖区内多样化且不断变化的医疗保健法规的挑战。遵守临床试验通讯协定、资料隐私法和财务报告准则进一步增加了风险和成本。监管核准的延迟和政策变化会影响公司估值和投资者信心。为了应对这些挑战，公司必须投资法律专业知识、透明的管治和适应性策略，以满足全球监管要求。

新冠疫情的影响：

新冠疫情对医疗保健IPO市场产生了复杂的影响。疫情一方面扰乱了临床试验，延缓了监管审批，另一方面也凸显了医疗创新的重要性。疫苗、诊断和数位医疗解决方案的研发企业获得了投资者的更多关注，IPO进程也随之加快。此次危机也凸显了敏捷、以科学为主导的企业的价值，推动了医疗保健相关企业数量的激增。疫情过后，市场持续受益于更强的市场韧性以及公共和私人对技术进步的更多投资。

预计在预测期内，生技公司板块将占据最大的市场份额。

预计在预测期内，生技公司将占据最大的市场份额。生物技术公司处于医疗创新前沿，致力于开发癌症、罕见疾病和慢性病的治疗方法。其高成长潜力和频繁的突破性进展吸引了投资者的浓厚兴趣。首次公开发行（IPO）是临床试验、监管核准和商业化的重要资金来源。随着个人化医疗和基因疗法日益受到关注，生物技术公司主导IPO市场，推动资本流入和医疗保健领域的变革性进步。

预计在预测期内，循环系统领域将实现最高的复合年增长率。

预计在预测期内，循环系统领域将呈现最高的成长率，这主要得益于循环系统疾病盛行率的上升、人口老化以及对先进诊断和治疗方法需求的不断增长。开发创新心臟设备、数位监测工具和微创疗法的公司正吸引投资者的目光。首次公开募股（IPO）将使这些公司能够扩大研发规模、提升生产能力并进入新市场。鑑于心臟健康仍然是全球关注的焦点，心臟病学领域的快速技术创新和临床相关性有望推动IPO活动的加速和持续成长。

占比最大的地区：

预计亚太地区将在预测期内保持最大的市场份额，这主要得益于该地区不断扩大的医疗基础设施、日益​​壮大的中产阶级以及政府对生物技术创新的支持，这些因素将推动市场成长。中国、印度和韩国等国家已培育出充满活力的Start-Ups生态系统，并为企业提供了便利的资本市场进入管道。当地交易所正吸引许多医疗健康相关企业上市，而全球投资者也积极寻求在亚洲蓬勃发展的医疗健康领域投资的机会。这一发展势头将使亚太地区在医疗健康IPO领域占据主导地位。

复合年增长率最高的地区：

预计北美在预测期内将呈现最高的复合年增长率。这主要得益于该地区强大的生命科学生态系统、活跃的创业投资投资以及有利的法规环境，这些因素共同支持了IPO的快速成长。总部位于美国的生物技术和医疗技术公司在创新方面处于领先地位，并经常透过IPO为临床试验和商业化资金筹措。数位医疗和个人化医疗的兴起进一步推动了上市进程。凭藉成熟的资本市场和投资者对医疗保健创新的浓厚兴趣，北美仍然是高成长医疗保健IPO的热点地区。

免费客製化服务：

购买此报告的客户可以选择以下免费自订选项之一：

  • 公司概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要参与者（最多3家公司）的SWOT分析
  • 区域细分
    • 根据客户要求，对主要国家的市场规模进行估算和预测，併计算复合年增长率（註：可行性需确认）。
  • 竞争基准化分析
    • 根据主要参与者的产品系列、地理覆盖范围和策略联盟基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 原始研究资料
    • 次级研究资讯来源
    • 先决条件

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球医疗保健 IPO 市场（以营业单位类型划分）

  • 製药公司
  • 生技公司
  • 医疗设备製造商
  • 诊断和实验室服务
  • 医疗保健服务和提供者
  • 数位健康和​​医疗保健资讯技术

6. 全球医疗保健IPO市场：按IPO规模和结构划分

  • 小型股IPO
  • 中型IPO
  • 大型IPO
  • SPAC合併和反向收购

7. 全球医疗保健IPO市场（依投资者类型划分）

  • 机构投资者
  • 个人投资者
  • 创业投资与私募股权
  • 策略企业投资者

第八章：全球医疗保健IPO市场（依上市市场划分）

  • 主要交易所
  • 区域交易所
  • 交叉上市和美国存託凭证

9. 全球医疗保健IPO市场（依治疗领域划分）

  • 肿瘤学
  • 心臟病学
  • 罕见疾病和孤儿药
  • 基因和细胞疗法
  • 数位疗法和人工智慧诊断

10. 全球医疗保健IPO市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与併购
  • 新产品上市
  • 业务拓展
  • 其他关键策略

第十二章 企业概况

  • Galderma SA
  • BrightSpring Health Services
  • Concentra Group Holdings
  • PACS Group Inc.
  • CG Oncology Inc.
  • Tempus AI Inc.
  • Auna SA
  • Emcure Pharmaceuticals Ltd.
  • Sai Life Sciences Ltd.
  • Sagility India Ltd.
  • Hinge Health
  • Omada Health
  • Kyverna Therapeutics Inc.
  • Bicara Therapeutics Inc.
  • Ardent Health Partners Inc.
Product Code: SMRC32126

According to Stratistics MRC, the Global Healthcare IPOs Market is accounted for $1.8 billion in 2025 and is expected to reach $2.8 billion by 2032 growing at a CAGR of 6.3% during the forecast period. Healthcare IPOs refer to the initial public offerings of companies operating within the healthcare sector, including pharmaceuticals, biotechnology, medical devices, diagnostics, and digital health. These IPOs allow private healthcare firms to raise capital by offering shares to the public for the first time, enabling expansion, research, and innovation. Healthcare IPOs are often driven by breakthroughs in medical technology, regulatory approvals, and investor interest in life sciences. They play a crucial role in funding high-growth ventures and advancing public access to cutting-edge treatments. Market performance can be influenced by clinical trial results, policy changes, and broader economic conditions.

Market Dynamics:

Driver:

Rapid innovation in health tech

Rapid innovation in health technology is a key driver of the Healthcare IPOs Market. Breakthroughs in biotechnology, digital health, AI-driven diagnostics, and wearable medical devices are transforming patient care and creating high-growth opportunities. These advancements attract investor interest and accelerate the path to public offerings. Startups and established firms alike seek IPOs to fund R&D, scale operations, and commercialize novel treatments. As health tech continues to evolve, it fuels a dynamic IPO landscape that supports innovation and expands access to cutting-edge healthcare solutions.

Restraint:

Stricter IPO criteria

Stricter IPO criteria present a significant restraint to the Healthcare IPOs Market. Regulatory bodies and stock exchanges have tightened listing requirements to ensure transparency, financial stability, and investor protection. These include rigorous financial disclosures, clinical trial validations, and governance standards. While these measures enhance market integrity, they can delay or deter IPO plans, especially for early-stage healthcare firms. Navigating these hurdles requires robust compliance strategies and investor readiness, making it challenging for some companies to access public capital markets efficiently.

Opportunity:

Digital healthcare expansion

The expansion of digital healthcare presents a major opportunity for the Healthcare IPOs Market. Telemedicine, remote monitoring, AI-powered diagnostics, and health data platforms are reshaping care delivery. As demand for accessible, tech-enabled healthcare grows, digital health startups are attracting significant venture capital and preparing for public listings. IPOs provide the funding needed to scale platforms, enhance cybersecurity, and expand global reach. This digital transformation is unlocking new revenue streams and positioning healthcare IPOs as a gateway to next-generation medical innovation.

Threat:

Regulatory complexity

Regulatory complexity poses a notable threat to the Healthcare IPOs Market. Navigating diverse and evolving healthcare regulations across jurisdictions can be daunting for companies seeking to go public. Compliance with clinical trial protocols, data privacy laws, and financial reporting standards adds layers of risk and cost. Delays in regulatory approvals or policy shifts can impact valuation and investor confidence. To mitigate these challenges, firms must invest in legal expertise, transparent governance, and adaptive strategies to align with global regulatory expectations.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the Healthcare IPOs Market. While it disrupted clinical trials and delayed regulatory reviews, it also spotlighted the importance of healthcare innovation. Companies developing vaccines, diagnostics, and digital health solutions experienced heightened investor interest and accelerated IPO timelines. The crisis underscored the value of agile, science-driven firms, leading to a surge in healthcare listings. Post-pandemic, the market continues to benefit from increased public and private investment in health resilience and technological advancement.

The biotechnology firms segment is expected to be the largest during the forecast period

The biotechnology firms segment is expected to account for the largest market share during the forecast period, as biotech companies are at the forefront of medical innovation, developing therapies for cancer, rare diseases, and chronic conditions. Their high growth potential and frequent breakthroughs attract strong investor interest. IPOs provide critical funding for clinical trials, regulatory approvals, and commercialization. As personalized medicine and gene therapies gain traction, biotech firms dominate the IPO landscape, driving both capital inflow and transformative healthcare advancements.

The cardiology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cardiology segment is predicted to witness the highest growth rate, due to rising prevalence of cardiovascular diseases, aging populations, and demand for advanced diagnostics and treatments fuel growth. Companies developing innovative cardiac devices, digital monitoring tools, and minimally invasive procedures are gaining investor attention. IPOs enable these firms to expand R&D, scale production, and enter new markets. As heart health remains a global priority, the cardiology segment's rapid innovation and clinical relevance position it for accelerated IPO activity and sustained growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to region's expanding healthcare infrastructure, rising middle-class population, and government support for biotech innovation drive market growth. Countries like China, India, and South Korea are fostering vibrant startup ecosystems and easing access to capital markets. Local exchanges are attracting healthcare listings, while global investors seek exposure to Asia's dynamic health sector. This momentum positions Asia Pacific as a dominant force in healthcare IPO activity.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to region's robust life sciences ecosystem, strong venture capital presence, and favorable regulatory environment support rapid IPO growth. U.S.-based biotech and medtech firms lead in innovation, frequently leveraging IPOs to fund clinical trials and commercialization. The rise of digital health and personalized medicine further fuels listings. With mature capital markets and investor appetite for healthcare innovation, North America remains a hotspot for high-growth healthcare IPOs.

Key players in the market

Some of the key players in Healthcare IPOs Market include Galderma S.A., BrightSpring Health Services, Concentra Group Holdings, PACS Group Inc., CG Oncology Inc., Tempus AI Inc., Auna S.A., Emcure Pharmaceuticals Ltd., Sai Life Sciences Ltd., Sagility India Ltd., Hinge Health, Omada Health, Kyverna Therapeutics Inc., Bicara Therapeutics Inc., Ardent Health Partners Inc.

Key Developments:

In January 2025, Syensqo and Ardent Process Technologies have formalised a strategic partnership to accelerate point-source carbon capture and olefin-paraffin separation technologies, combining Syensqo's materials science prowess and industrial scale with Ardent's high-performance membrane solutions.

In October 2024, L'Oreal Groupe has acquired a 10 % stake in Galderma Group AG and entered a strategic scientific partnership, combining Galderma's dermatology-solutions expertise with L'Oreal's strengths in skin-biology, diagnostic tools and evaluation methods to accelerate innovation in the aesthetics and dermatology space.

Entity Types Covered:

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Medical Device Manufacturers
  • Diagnostics & Laboratory Services
  • Healthcare Services & Providers
  • Digital Health & Health IT

IPO Sizes & Structures Covered:

  • Small-cap IPOs
  • Mid-cap IPOs
  • Large-cap IPOs
  • SPAC Mergers & Reverse Mergers

Investor Types Covered:

  • Institutional Investors
  • Retail Investors
  • Venture Capital & Private Equity
  • Strategic Corporate Investors

Listing Venues Covered:

  • Major Exchanges
  • Regional Exchanges
  • Cross-Listings & ADRs

Therapeutic Areas Covered:

  • Oncology
  • Cardiology
  • Rare Diseases & Orphan Drugs
  • Gene & Cell Therapies
  • Digital Therapeutics & AI Diagnostics

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Healthcare IPOs Market, By Entity Type

  • 5.1 Introduction
  • 5.2 Pharmaceutical Companies
  • 5.3 Biotechnology Firms
  • 5.4 Medical Device Manufacturers
  • 5.5 Diagnostics & Laboratory Services
  • 5.6 Healthcare Services & Providers
  • 5.7 Digital Health & Health IT

6 Global Healthcare IPOs Market, By IPO Size & Structure

  • 6.1 Introduction
  • 6.2 Small-cap IPOs
  • 6.3 Mid-cap IPOs
  • 6.4 Large-cap IPOs
  • 6.5 SPAC Mergers & Reverse Mergers

7 Global Healthcare IPOs Market, By Investor Type

  • 7.1 Introduction
  • 7.2 Institutional Investors
  • 7.3 Retail Investors
  • 7.4 Venture Capital & Private Equity
  • 7.5 Strategic Corporate Investors

8 Global Healthcare IPOs Market, By Listing Venue

  • 8.1 Introduction
  • 8.2 Major Exchanges
  • 8.3 Regional Exchanges
  • 8.4 Cross-Listings & ADRs

9 Global Healthcare IPOs Market, By Therapeutic Area

  • 9.1 Introduction
  • 9.2 Oncology
  • 9.3 Cardiology
  • 9.4 Rare Diseases & Orphan Drugs
  • 9.5 Gene & Cell Therapies
  • 9.6 Digital Therapeutics & AI Diagnostics

10 Global Healthcare IPOs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Galderma S.A.
  • 12.2 BrightSpring Health Services
  • 12.3 Concentra Group Holdings
  • 12.4 PACS Group Inc.
  • 12.5 CG Oncology Inc.
  • 12.6 Tempus AI Inc.
  • 12.7 Auna S.A.
  • 12.8 Emcure Pharmaceuticals Ltd.
  • 12.9 Sai Life Sciences Ltd.
  • 12.10 Sagility India Ltd.
  • 12.11 Hinge Health
  • 12.12 Omada Health
  • 12.13 Kyverna Therapeutics Inc.
  • 12.14 Bicara Therapeutics Inc.
  • 12.15 Ardent Health Partners Inc.

List of Tables

  • Table 1 Global Healthcare IPOs Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Healthcare IPOs Market Outlook, By Entity Type (2024-2032) ($MN)
  • Table 3 Global Healthcare IPOs Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 4 Global Healthcare IPOs Market Outlook, By Biotechnology Firms (2024-2032) ($MN)
  • Table 5 Global Healthcare IPOs Market Outlook, By Medical Device Manufacturers (2024-2032) ($MN)
  • Table 6 Global Healthcare IPOs Market Outlook, By Diagnostics & Laboratory Services (2024-2032) ($MN)
  • Table 7 Global Healthcare IPOs Market Outlook, By Healthcare Services & Providers (2024-2032) ($MN)
  • Table 8 Global Healthcare IPOs Market Outlook, By Digital Health & Health IT (2024-2032) ($MN)
  • Table 9 Global Healthcare IPOs Market Outlook, By IPO Size & Structure (2024-2032) ($MN)
  • Table 10 Global Healthcare IPOs Market Outlook, By Small-cap IPOs (2024-2032) ($MN)
  • Table 11 Global Healthcare IPOs Market Outlook, By Mid-cap IPOs (2024-2032) ($MN)
  • Table 12 Global Healthcare IPOs Market Outlook, By Large-cap IPOs (2024-2032) ($MN)
  • Table 13 Global Healthcare IPOs Market Outlook, By SPAC Mergers & Reverse Mergers (2024-2032) ($MN)
  • Table 14 Global Healthcare IPOs Market Outlook, By Investor Type (2024-2032) ($MN)
  • Table 15 Global Healthcare IPOs Market Outlook, By Institutional Investors (2024-2032) ($MN)
  • Table 16 Global Healthcare IPOs Market Outlook, By Retail Investors (2024-2032) ($MN)
  • Table 17 Global Healthcare IPOs Market Outlook, By Venture Capital & Private Equity (2024-2032) ($MN)
  • Table 18 Global Healthcare IPOs Market Outlook, By Strategic Corporate Investors (2024-2032) ($MN)
  • Table 19 Global Healthcare IPOs Market Outlook, By Listing Venue (2024-2032) ($MN)
  • Table 20 Global Healthcare IPOs Market Outlook, By Major Exchanges (2024-2032) ($MN)
  • Table 21 Global Healthcare IPOs Market Outlook, By Regional Exchanges (2024-2032) ($MN)
  • Table 22 Global Healthcare IPOs Market Outlook, By Cross-Listings & ADRs (2024-2032) ($MN)
  • Table 23 Global Healthcare IPOs Market Outlook, By Therapeutic Area (2024-2032) ($MN)
  • Table 24 Global Healthcare IPOs Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 25 Global Healthcare IPOs Market Outlook, By Cardiology (2024-2032) ($MN)
  • Table 26 Global Healthcare IPOs Market Outlook, By Rare Diseases & Orphan Drugs (2024-2032) ($MN)
  • Table 27 Global Healthcare IPOs Market Outlook, By Gene & Cell Therapies (2024-2032) ($MN)
  • Table 28 Global Healthcare IPOs Market Outlook, By Digital Therapeutics & AI Diagnostics (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.